Cambridge Research Biochemicals News and Blog

Latest news

20 May 2014

Cambridge Research Biochemicals renews Supply Contract with the Medical Research Council for a fourth year

Cambridge Research Biochemicals (CRB), offering expertise in the custom supply of research reagents, principally peptides and antibodies, has once again demonstrated customer satisfaction with the extension of an important contract in the medical research field.

CRB, based in the North East of England in Billingham on Teesside, has announced renewal of its contract with UK SBS, formerly known as RCUK Shared Services Centre Ltd (RCUK SSC Ltd) for a fourth year, with the original contract being issued in 2010.

Renewal of this contract is extremely significant to CRB as it not only consolidates the existing relationships with the Medical Research Council (MRC), but also allows the company to continue to enhance and progress relations with new MRC Institutes in addition to exploring avenues into other UK based Research Institutes and Universities. CRB comments that renewal of the contract further strengthens its position as a key supplier of custom-synthesised peptides and bespoke polyclonal and monoclonal antibodies.

Under the new contract, CRB will continue to supply the MRC with custom-synthesised peptides and custom-generated polyclonal and monoclonal antibodies for a further 12 months.

Cambridge Research Biochemicals (CRB) Commercial Director Emily Humphrys said: “This is an important announcement for CRB, as it demonstrates that we are delivering a consistently high level of quality life-science tools to the Medical Research Council.”

“The recent expansion and relocation of CRB and investment of £1M has allowed us to expand the peptide and antibody portfolio offered to the MRC further still. This includes monoclonal antibodies to be generated in our new cell culture suite, in addition to the current selection of highly versatile and top quality research peptide and polyclonal antibody tools. The peptide chemistry operation has also increased capacity, allowing CRB to offer a wider range of targets and more creative and complex modifications.”

“The contract renewal also signifies the progress and commitment to quality that CRB have made over the past four years since the agreement was first established. This is a demanding and competitive field and the renewal of the contract recognises both our dedication to the very highest technical and service standards and furthermore, the trust and confidence that the Medical Research Council has placed in CRB.”

Mike Reilly, Category Manager for UK SBS Ltd, said: “The renewal of this contract illustrates the faith that we have in the excellent work being done by the team at CRB. During the time that we have worked together, they have constantly operated under a high level of professionalism and exhibited an impressive commitment to the quality and ethical standards of the products that they supply to us. We look forward to continuing to develop our relationship in the years to come.”